Bradley D Jones Selected Research

Infections

12/2021	Type IV Pili of Streptococcus sanguinis Contribute to Pathogenesis in Experimental Infective Endocarditis.
1/2021	Photograftable Zwitterionic Coatings Prevent Staphylococcus aureus and Staphylococcus epidermidis Adhesion to PDMS Surfaces.
1/2018	Bacterial lipoproteins and other factors released by Francisella tularensis modulate human neutrophil lifespan: Effects of a TLR1 SNP on apoptosis inhibition.
10/2016	Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.
1/2016	Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.
1/2015	Interactions of Francisella tularensis with Alveolar Type II Epithelial Cells and the Murine Respiratory Epithelium.
7/2014	Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.
3/2013	Disruption of Francisella tularensis Schu S4 iglI, iglJ, and pdpC genes results in attenuation for growth in human macrophages and in vivo virulence in mice and reveals a unique phenotype for pdpC.
1/2013	Francisella tularensis live vaccine strain folate metabolism and pseudouridine synthase gene mutants modulate macrophage caspase-1 activation.
9/2010	Cutting edge: mutation of Francisella tularensis mviN leads to increased macrophage absent in melanoma 2 inflammasome activation and a loss of virulence.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bradley D Jones Research Topics

Disease

15	Infections 12/2021 - 06/2002
5	Tularemia 01/2018 - 10/2010
1	Bacterial Infections (Bacterial Infection) 01/2021
1	Endocarditis 01/2020
1	Hypoxia (Hypoxemia) 01/2016
1	Melanoma (Melanoma, Malignant) 09/2010

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2010
2	VaccinesIBA 10/2016 - 01/2016
2	Capsules (Microcapsules)IBA 01/2016 - 01/2015
2	AntibodiesIBA 01/2016 - 10/2010
2	SterolsIBA 02/2004 - 06/2002
2	CholesterolIBA 02/2004 - 06/2002
1	Extracellular Matrix ProteinsIBA 12/2021
1	PolymersIBA 01/2021
1	Conjugate VaccinesIBA 01/2021
1	Virulence Factors (Pathogenicity Factors)IBA 01/2020
1	Conditioned Culture MediaIBA 01/2018
1	bacterioferritinIBA 01/2018
1	Biological Warfare AgentsIBA 10/2017
1	EpitopesIBA 10/2016
1	CytokinesIBA 01/2016
1	GlycoconjugatesIBA 01/2016
1	prenylIBA 07/2014
1	Bacterial VaccinesIBA 07/2014
1	Diphosphates (Pyrophosphates)IBA 07/2014
1	SugarsIBA 04/2014
1	O Antigens (O Antigen)IBA 04/2014
1	LipopolysaccharidesIBA 04/2014
1	1- palmitoyl- 2- docosahexaenoyl- sn- glycero- 3- phosphocholine (PDPC)IBA 03/2013
1	pseudouridine synthasesIBA 01/2013
1	Interleukin-18 (Interleukin 18)IBA 01/2013
1	Caspase 1 (ICE Protease)IBA 09/2010
1	InflammasomesIBA 09/2010
1	Interleukin-8 (Interleukin 8)IBA 04/2009
1	Interleukin-1beta (Interleukin 1 beta)IBA 04/2009
1	Protease La (Endopeptidase La)IBA 04/2004
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2004
1	Oxygen (Dioxygen)IBA 01/2003
1	Type III Secretion SystemsIBA 01/2003
1	LipidsIBA 06/2002